JD Health International (HKG:6618) recorded a profit attributable to the owners of 4.16 billion yuan in 2024, 94% higher than 2.14 billion yuan from 2023, a Thursday Hong Kong bourse filing said.
The earnings per share were 1.32 yuan, compared with 0.68 yuan per share from a year earlier.
The digital health services company's revenue for the year came in at 58.2 billion yuan, 8.6% higher than 53.5 billion yuan of the preceding year.
The increase in revenue is attributed to an increase in revenue from the sales of pharmaceutical and healthcare products resulting from an increase in active user accounts, additional purchases, and the increase in online product sales.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。